These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34674146)

  • 1. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
    Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
    Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
    Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
    Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
    Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
    [No Abstract]   [Full Text] [Related]  

  • 4. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.
    Saltiki K; Simeakis G; Karapanou O; Paschou SA; Alevizaki M
    Endocrine; 2023 Jun; 80(3):570-579. PubMed ID: 36626081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 6. An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.
    Shete J; AlSaleh K; Safwat R; Bedair A; ElSherify M; Hussein A; Nazeeh M; Mohanty A
    Gulf J Oncolog; 2020 Sep; 1(34):39-47. PubMed ID: 33431361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
    Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience.
    Pitoia F; Abelleira E; Román-González A; Danilovic DLS; Scheffel RS; Maia AL; Hoff AO; Califano I
    Thyroid; 2024 Jul; 34(7):949-952. PubMed ID: 38757613
    [No Abstract]   [Full Text] [Related]  

  • 12. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
    Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
    Hadoux J; Schlumberger M
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
    Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
    Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
    Maciel LMZ; Magalhães PKR
    Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastropharyngeal Anastomotic Leak in Medullary Thyroid Carcinoma Following Initiation of a Tyrosine Kinase Inhibitor: A Case Report of an Unusual Side Effect of Cabozantinib.
    Ackerman J; Kent S; Walker P
    Ann Otol Rhinol Laryngol; 2020 Jul; 129(7):657-661. PubMed ID: 32037846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Postoperative external beam radiotherapy for medullary thyroid carcinoma with high risk of locoregional relapse].
    Compagnon F; Zerdoud S; Rives M; Laprie A; Sarini J; Grunenwald S; Chaltiel L; Graff P
    Cancer Radiother; 2016 Jul; 20(5):362-9. PubMed ID: 27396902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An audit of medullary thyroid carcinoma from a tertiary care hospital in northwest India.
    Chakraborty AM; Rai A; Pal R; Mukherjee S; Dahiya D; Kumar R; Saikia UN; Panda NK; Bhadada SK; Dutta P
    Front Endocrinol (Lausanne); 2023; 14():1226348. PubMed ID: 38260132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.